Telehealth Companies Strengthen D.C. Lobbying On Compounding, Rx Drugs, Medicare Flexibilities

By Christian Robles / July 29, 2025 at 5:23 PM

Individual telehealth companies have intensified their Washington lobbying efforts since the Trump administration took office amid regulatory limits on their ability to prescribe compounded GLP-1s and a looming Sept. 30 deadline for extension of Medicare telehealth flexibilities, an Inside Health Policy review of 2025 Q1 and Q2 House lobbying disclosures found.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.